文献速递泌尿生殖与妇科肿瘤放疗乳腺癌放疗放疗物理与技术

前列腺癌预防性乳腺放疗是否增加乳腺癌风险

Does Prophylactic Radiation Therapy to Avoid Gynecomastia in Patients With Prostate Cancer Increase the Risk of Breast Cancer?
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2018-02-05

该登记研究纳入1997至2014年挪威癌症登记中首发诊断为前列腺癌的59169例患者,其中7864例(13.3%)接受预防性乳腺放疗以预防男性乳腺发育。中位随访4年,12例发生乳腺癌,其中3例曾接受预防性放疗。预防性放疗组乳腺癌风险与非放疗组无统计学差异(亚分布风险比1.62,95%CI 0.41-5.62),标化发病比为0.996(95%CI 0.57-1.75)。

要点

  • 预防性乳腺放疗组与非放疗组的乳腺癌风险无统计学差异(亚分布风险比1.62,95%CI 0.41-5.62)。
  • 队列标化发病比为0.996(95%CI 0.57-1.75),与标准男性人群相比未见升高。
  • 12例乳腺癌中3例曾接受预防性放疗,其中2例为叶状肿瘤。

核心结论

  • 在本登记研究中,接受预防性乳腺放疗的前列腺癌患者未见乳腺癌风险升高,继发乳腺癌风险似乎可忽略。

研究设计与样本

  • 基于挪威癌症登记,收集1997至2014年以乳腺癌为第一诊断的前列腺癌患者数据,登记同期全部放疗及前列腺癌诊断≥3个月后发生的乳腺癌。
  • 共分析59169例前列腺癌患者,其中7864例(13.3%)接受预防性乳腺放疗,中位随访4年,估计亚分布风险比并计算标化发病比。

主要发现

  • 12例患者诊断乳腺癌,其中3例曾接受预防性放疗,2例为叶状肿瘤。
  • 预防性放疗组与非放疗组乳腺癌风险无统计学差异(亚分布风险比1.62,95%CI 0.41-5.62,校正年龄和诊断时间)。
  • 标化发病比为0.996(95%CI 0.57-1.75)。

临床怎么用

  • 对于接受抗雄激素单药治疗并考虑预防性乳腺放疗以预防男性乳腺发育的前列腺癌患者,本研究未显示乳腺癌风险增加。
  • 鉴于乳腺癌病例数少,仍需在随访中关注乳腺变化,尤其是叶状肿瘤等罕见类型。

局限性

  • 乳腺癌病例数少,随着随访时间延长乳腺癌发生率可能增加。
  • 为登记研究,可能存在未校正的混杂因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Prostate cancer (PC) patients who undergo antiandrogen monotherapy are offered prophylactic radiation therapy (PRT) to the breast buds to avoid gynecomastia. The aim of the present study was to evaluate whether the risk of breast cancer (BC) in men with PC as their first cancer diagnosis was influenced by PRT. METHODS AND MATERIALS: From the Norwegian Cancer Registry, we collected data from all patients with PC as their first cancer diagnosis from 1997 to 2014. We registered all RT given to the patients in the same period and the occurrence of BC diagnosed ≥3 months after the PC diagnosis. The histopathologic diagnoses of all BC cases were collected. Subdistribution hazard ratios for the risk of BC in the PRT and non-PRT groups were estimated. A standardized incidence ratio for BC was calculated by comparing our cohort to the standard male population. RESULTS: We analyzed 59,169 patients with PC, of whom 7864 (13.3%) had received PRT. The median follow-up time was 4 years. Of the 12 men with a diagnosis of BC, 3 had received PRT, and 2 of the 3 were phyllodes tumors. The risk of BC was not significantly different statistically for the patients given PRT compared with the non-PRT group (subdistribution hazard ratio 1.62, 95% confidence interval 0.41-5.62, adjusted for age and time of diagnosis). The standardized incidence ratio was 0.996 (95% confidence interval 0.57-1.75). CONCLUSIONS: In this registry-based study, we did not find an increased risk of BC in PC patients who received PRT. The number of BC cases in our study was low, and the risk of secondary BC after PRT seems to be negligible. The incidence of BC could, however, increase with additional follow-up. Also, 2 patients who had received PRT developed a malignant phyllodes tumor, an extremely rare type of BC associated with gynecomastia.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Aksnessæther BY, Solberg A, Klepp OH, et al. Does Prophylactic Radiation Therapy to Avoid Gynecomastia in Patients With Prostate Cancer Increase the Risk of Breast Cancer? Int J Radiat Oncol Biol Phys. 2018. PMID: 29534900. doi:10.1016/j.ijrobp.2018.01.096

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。